MoneyWorks4Me

Biocon informs about press release

23 Dec 2025 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..